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CORRESPONDENCE

Letter: Considerations for Performing
Emergent Neurointerventional Procedures in a
COVID-19 Environment
To the Editor:
COVID-19 syndrome, caused by the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) virus, most commonly
presents with upper respiratory infectious symptoms and may
lead to hypoxemic failure, the most common cause of ventilation support.1-5 There may be a hypercoagulable state during
SARS-CoV-2 infections that could lead to an increased vascular
thrombotic phenomenon and a potential need for neurointerventional procedures.6-8 We aim to outline practices to be considered
when managing COVID-19 patients requiring neurointerventional care.

GENERAL PLANNING
Given the number of SARS-CoV-2 infections within the
community, patients presenting with neurological emergencies
needing immediate interventional therapy will not be able to
be tested in time, and thus such patients should be considered
as persons under investigation (PUIs) for SARS-CoV-2 viral
infection.4 Care of such patients should be performed with
maximal personal protective equipment (PPE), including N95
masks.9,10
•
•

All patients needing emergent neurointerventional procedures should be considered PUIs.
Maximal PPE should be employed when performing
emergent neurointerventional procedures on COVID-19 or
PUI patients.

Personnel
It is ideal to minimize the number of neurointerventional
radiology (NIR) attendings, fellows, nurses, and technologists
who are in-house at any one time to minimize personnel exposure
to SARS-CoV-2.11 This is feasible with a general trend towards
canceling elective procedures during the pandemic. Members of
the NIR team need to be appropriately fitted with the N95 mask
and be aware as to how to obtain all appropriate PPE as N95s
may be stored in secure environments. Those who have facial
hair or cannot tolerate an N95 must be trained to use a powered
air purifying respirator (PAPR) or follow alternative institutional
protocols. One can reuse the N95 for up to 8 h without an outer
cover; however, when a face mask is worn over the N95 to prevent
gross contamination, its reuse can be extended.
During cases it is imperative that team members within the
NIR suite restrict their movement and not enter clean areas until
the procedure is completed and they have doffed their PPEs
appropriately. This will necessitate that a member of the team
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be placed in the clean control room to obtain the equipment
necessary during the procedure.
•
•
•
•

The number of NIR personnel within the hospital setting
should be minimal.
All team members must be fitted appropriately with N95
masks.
An outer standard surgical mask should be worn over the N95
to prolong the shelf life of the N95.
NIR personnel should be divided as such to prevent the
movement of NIR suite personnel to clean areas.

NIR Suite and Control Room
NIR suites are typically positive-pressure areas to minimize
outside infectious contaminants and prevent procedure-related
infections; however, this also increases the risk of spreading
aerosolized respiratory secretions from COVID-19 patients.
Reports from Singapore and New York University share the
idea of converting COVID-designated NIR suites into negativepressure areas with high efficiency particulate air (HEPA) filters,
thus reducing the risk of contaminating air flow systems and
minimizing the exposure of clean areas to infectious particulate
matter. While there may be a theoretical risk of increasing surgical
site infections (SSIs) in a negative-pressure environment, this may
be outweighed by the benefits of minimizing the exposure of clean
areas to infectious matter.12
If a facility has 2 NIR suites, one should become the designated
suite for COVID+/PUI patients and the other for documented
COVID-19-negative patients. The inventory in the COVID-19designated suite should remain in closed storage closets at all
times, or a barrier such as plastic sheets could be secured to cover
the inventory. Infrequently used inventory should be removed
from the suite and could be stored in the control room or an
adjacent anteroom.
In addition, you must determine if the control room attached
to the COVID NIR suite can be maintained as a clean
environment. This can be done if the pressure of the control
room can be changed to be higher than that of the NIR suite.
If this can be achieved, then portable material within the NIR
suite can be moved to the control room. If the control room
cannot be maintained as a clean environment, then it is ideal to
move nonessential portable equipment from the control room,
as it also may require a terminal clean. All COVID-contaminated
areas (NIR suite and possibly the control room) will need terminal
cleaning from ceiling to floor, including the lights and air ducts.
•
•

Designate one NIR suite as COVID NIR and remove all
portable equipment that may get contaminated.
Predetermine supplies needed for the NIR case and take those
to COVID NIR.
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•
•

Keep the clean control room entrance to the COVID NIR
room closed at all times during the procedure.
Maintain 1 team member in the NIR control room to seek
needed supplies.

Anteroom
An anteroom serves as a gateway from the COVID-designated
NIR suite to the halls, preventing infectious particulate matter
from reaching the halls.13 The anteroom is a small area outside
of the NIR suite under negative pressure and fitted with a HEPA
filter allowing for personnel to remove their PPE and wash
hands before entering a clean area. The negative pressure within
the anteroom prevents contaminated particulate matter from
traveling to other parts of the hospital. Most NIR suites may
not have an attached anteroom, thus engineering staff should
be contacted to build a portable anteroom for the COVID NIR
suite.
•

Build an anteroom attached to the COVID-NIR suite to
prevent contamination of adjacent clean areas.

PREOPERATIVE, OPERATIVE, AND
POSTOPERATIVE BEST PRACTICES
Transfer from emergency department (ED) to NIR Room
All nonintubated patients being transported should have a face
mask in place. For an intubated patient, it is safest to maintain a
closed circuit until after the procedure is concluded. If that is not
possible, extreme caution must be taken while clamping the tube
when transferring from bagging to ventilator, or ideally the patient
may remain on a single ventilator from ED until after treatment,
when the ventilator can be changed in a negative-pressure setting.
•
•
•

All personnel working with COVID-19 patients should have
maximal PPE.
A face mask should be placed on all nonintubated patients
during transport.
Endotracheal tubes should be clamped before transferring to
ventilator.

Intubation and Procedure
With most NIR emergencies (subarachnoid hemorrhage,
carotid blow out, epistaxis, etc), intubation becomes essential for
the protection of the airway; however, with large vessel occlusion
(LVO)-related ischemic stroke, there continues to be a lack of
guidance for the best practice. If intubation is to be performed, it
should ideally be performed in a negative-pressure environment to
minimize the contamination of adjacent areas and personnel, and
hypotension should be avoided in stroke patients.14 If intubation
must be performed in the NIR suite, then only anesthesia staff
donning appropriate PPE should be present within the room,
and postintubation a barrier around the patient’s face should
be applied to contain aerosolization.15 Before entering the NIR
suite, you should wait for a period of time (determined by your
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engineering team) to minimize aerosolized particulate matter
within the NIR environment; however, such delays will not be
ideal in cases of LVO-related stroke patients. If a negative-pressure
room is available, full recirculation time is typically around 3
min, so staff may re-enter the room within 5 min.
Other centers have not changed their anesthesia/intubation
paradigms secondary to the COVID status. In these circumstances, patients remain on nasal cannula O2 with a face mask,
and there is not a need to extubate, which is the largest producer
of aerosolized matter. Thus, performing thrombectomies without
intubation allows for the avoidance of intubation and extubation
(highest risk of aerosolization), risk of patient continuing to be
intubated and requiring ventilator and intensive care unit (ICU)
room, and prolonged recovery times.
•
•
•
•

Intubation and extubation lead to maximal aerosolization and
contamination.
Intubation and extubation should ideally be performed in
negative-pressure rooms.
NIR personnel should not be present for intubations/extubations.
NIR should enter with appropriate PPE once airway is secure
and patient face barrier is in place.

Extubation and Transfer to Final Destination
While it is ideal if resources allow for the transport of an
intubated patient into a negative-pressure room to extubate, this
may be unlikely given the rise in the COVID patient population
requiring critical care services and negative-pressure rooms. Thus,
if possible, extubate the patient within the NIR environment
under the same conditions as described for intubation. Once
the patient is extubated and has stopped coughing, it is ideal to
transport to the final destination rather than an intermediary stop
within the postanesthesia care unit (PACU). This will minimize
contamination during transport and minimize the number of
healthcare personnel exposed. For those patients not intubated,
extubation is avoided; however, they should also be transported to
the final destination with a face mask and without stopping in a
PACU environment. Flat-panel detector computed tomography
(CT) scanning capabilities of modern angiographic equipment
may also reduce the need to transport to postprocedure CT.
•
•
•

Extubate with a minimal number of surrounding personnel
(must use N95s).
Transfer the patient to the final destination rather than an
intermediary location (PACU).
Terminal clean the COVID NIR suite.

CONCLUSION
The COVID-19 pandemic is affecting most regions of the
United States, necessitating a change in our practice patterns. We
have outlined general principles to be taken into consideration as
neurointerventional teams look to care for their patients while
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